Stay Up to Date
Breaking News,
Updates, & More
Click Here to

TOP - August 2011 Vol 4, No 5

CHICAGO—The phase 3 ACT-1 trial suggests that amrubicin may have some advantages over topotecan as secondline treatment for small-cell lung cancer (SCLC).
CHICAGO—Several studies addressed key questions in the treatment of non-Hodgkin lymphoma (NHL). One evaluated a shorter, more intense rituximab- based regimen, and another evaluated the benefit of autologous stem-cell transplantation (ASCT) in high-risk patients.
TOP - August 2011 Vol 4, No 5 published on August 25, 2011 in Breast Cancer

For breast cancer patients aged 66 years and older, nurses should consider comorbidities when discussing prognosis, according to an analysis of Surveillance, Epidemiology and End Results–Medicare data.

Page 2 of 2
Results 11 - 13 of 13